These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 36971061)

  • 1. Idelalisib plus rituximab versus ibrutinib in the treatment of relapsed/refractory chronic lymphocytic leukaemia: A real-world analysis from the Chronic Lymphocytic Leukemia Patients Registry (CLLEAR).
    Špaček M; Smolej L; Šimkovič M; Nekvindová L; Křístková Z; Brychtová Y; Panovská A; Mašlejová S; Bezděková L; Écsiová D; Vodárek P; Zuchnická J; Mihályová J; Urbanová R; Turcsányi P; Lysák D; Novák J; Brejcha M; Líkařová T; Vodička P; Baranová J; Trněný M; Doubek M;
    Br J Haematol; 2023 Jul; 202(1):40-47. PubMed ID: 36971061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Indirect Treatment Comparisons of Ibrutinib Versus Physician's Choice and Idelalisib Plus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia.
    Sorensen S; Wildgust M; Sengupta N; Trambitas C; Diels J; van Sanden S; Xu Y; Dorman E
    Clin Ther; 2017 Jan; 39(1):178-189.e5. PubMed ID: 28062113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia.
    Sharman JP; Coutre SE; Furman RR; Cheson BD; Pagel JM; Hillmen P; Barrientos JC; Zelenetz AD; Kipps TJ; Flinn IW; Ghia P; Eradat H; Ervin T; Lamanna N; Coiffier B; Pettitt AR; Ma S; Tausch E; Cramer P; Huang J; Mitra S; Hallek M; O'Brien SM; Stilgenbauer S
    J Clin Oncol; 2019 Jun; 37(16):1391-1402. PubMed ID: 30995176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparable Efficacy of Idelalisib Plus Rituximab and Ibrutinib in Relapsed/refractory Chronic Lymphocytic Leukemia: A Retrospective Case Matched Study of the Polish Adult Leukemia Group (PALG).
    Puła B; Budziszewska BK; Rybka J; Gil L; Subocz E; Długosz-Danecka M; Zawirska D; Waszczuk-Gajda A; Iskierka-Jażdżewska E; Kopacz A; Szymczyk A; Czyż J; Lech-Marańda E; Warzocha K; Jamroziak K
    Anticancer Res; 2018 May; 38(5):3025-3030. PubMed ID: 29715135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases.
    Morabito F; Tripepi G; Del Poeta G; Mauro FR; Reda G; Sportoletti P; Laurenti L; Coscia M; Herishanu Y; Bossio S; Varettoni M; Murru R; Chiarenza A; Visentin A; Condoluci A; Moia R; Pietrasanta D; Loseto G; Consoli U; Scortechini I; Rossi FM; Zucchetto A; Al-Janazreh H; Vigna E; Martino EA; Mendicino F; Cassin R; D'Arrigo G; Galimberti S; Rago A; Angeletti I; Biagi A; Del Giudice I; Bomben R; Neri A; Fronza G; Monti P; Menichini P; Cutrona G; Jaksic O; Rossi D; Di Raimondo F; Cuneo A; Gaidano G; Polliack A; Trentin L; Foà R; Ferrarini M; Gattei V; Gentile M
    Eur J Haematol; 2021 Apr; 106(4):493-499. PubMed ID: 33378569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.
    Chanan-Khan A; Cramer P; Demirkan F; Fraser G; Silva RS; Grosicki S; Pristupa A; Janssens A; Mayer J; Bartlett NL; Dilhuydy MS; Pylypenko H; Loscertales J; Avigdor A; Rule S; Villa D; Samoilova O; Panagiotidis P; Goy A; Mato A; Pavlovsky MA; Karlsson C; Mahler M; Salman M; Sun S; Phelps C; Balasubramanian S; Howes A; Hallek M;
    Lancet Oncol; 2016 Feb; 17(2):200-211. PubMed ID: 26655421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients.
    Mato AR; Hill BT; Lamanna N; Barr PM; Ujjani CS; Brander DM; Howlett C; Skarbnik AP; Cheson BD; Zent CS; Pu JJ; Kiselev P; Foon K; Lenhart J; Henick Bachow S; Winter AM; Cruz AL; Claxton DF; Goy A; Daniel C; Isaac K; Kennard KH; Timlin C; Fanning M; Gashonia L; Yacur M; Svoboda J; Schuster SJ; Nabhan C
    Ann Oncol; 2017 May; 28(5):1050-1056. PubMed ID: 28453705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial.
    Zelenetz AD; Barrientos JC; Brown JR; Coiffier B; Delgado J; Egyed M; Ghia P; Illés Á; Jurczak W; Marlton P; Montillo M; Morschhauser F; Pristupa AS; Robak T; Sharman JP; Simpson D; Smolej L; Tausch E; Adewoye AH; Dreiling LK; Kim Y; Stilgenbauer S; Hillmen P
    Lancet Oncol; 2017 Mar; 18(3):297-311. PubMed ID: 28139405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial.
    Jones JA; Robak T; Brown JR; Awan FT; Badoux X; Coutre S; Loscertales J; Taylor K; Vandenberghe E; Wach M; Wagner-Johnston N; Ysebaert L; Dreiling L; Dubowy R; Xing G; Flinn IW; Owen C
    Lancet Haematol; 2017 Mar; 4(3):e114-e126. PubMed ID: 28257752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-World Clinical Outcomes and Adverse Events in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib: A Single-Center Retrospective Study.
    Moldovianu AM; Stoia R; Vasilica M; Ursuleac I; Badelita SN; Tomescu AA; Preda OD; Bardas A; Cirstea M; Coriu D
    Medicina (Kaunas); 2023 Feb; 59(2):. PubMed ID: 36837525
    [No Abstract]   [Full Text] [Related]  

  • 12. BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.
    Perini GF; Feres CCP; Teixeira LLC; Hamerschlak N
    Curr Treat Options Oncol; 2021 Jun; 22(8):66. PubMed ID: 34110507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial.
    Sharman JP; Brander DM; Mato AR; Ghosh N; Schuster SJ; Kambhampati S; Burke JM; Lansigan F; Schreeder MT; Lunin SD; Zweibach A; Shtivelband M; Travis PM; Chandler JC; Kolibaba KS; Sportelli P; Miskin HP; Weiss MS; Flinn IW
    Lancet Haematol; 2021 Apr; 8(4):e254-e266. PubMed ID: 33631112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Idelalisib: A Novel PI3Kδ Inhibitor for Chronic Lymphocytic Leukemia.
    Shah A; Mangaonkar A
    Ann Pharmacother; 2015 Oct; 49(10):1162-70. PubMed ID: 26185276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Results from a Real-World Multicenter Analysis of 482 Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib: A Look at Racial Differences.
    Barrientos JC; Ayed AO; Cha A; Du S; Fang B; Hall R; Marks SM; Peng E; Rhodes JM; Ryan K; Winters SB; Yeung PL; Hou JZ
    Target Oncol; 2023 Sep; 18(5):727-734. PubMed ID: 37728835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-agent ibrutinib in RESONATE-2™ and RESONATE™ versus treatments in the real-world PHEDRA databases for patients with chronic lymphocytic leukemia.
    Salles G; Bachy E; Smolej L; Simkovic M; Baseggio L; Panovska A; Besson H; Healy N; Garside J; Iraqi W; Diels J; Pick-Lauer C; Spacek M; Urbanova R; Lysak D; Hermans R; Lundbom J; Callet-Bauchu E; Doubek M
    Ann Hematol; 2019 Dec; 98(12):2749-2760. PubMed ID: 31745601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study.
    Cuneo A; Mato AR; Rigolin GM; Piciocchi A; Gentile M; Laurenti L; Allan JN; Pagel JM; Brander DM; Hill BT; Winter A; Lamanna N; Tam CS; Jacobs R; Lansigan F; Barr PM; Shadman M; Skarbnik AP; Pu JJ; Sehgal AR; Schuster SJ; Shah NN; Ujjani CS; Roeker L; Orlandi EM; Billio A; Trentin L; Spacek M; Marchetti M; Tedeschi A; Ilariucci F; Gaidano G; Doubek M; Farina L; Molica S; Di Raimondo F; Coscia M; Mauro FR; de la Serna J; Medina Perez A; Ferrarini I; Cimino G; Cavallari M; Cucci R; Vignetti M; Foà R; Ghia P;
    Cancer Med; 2020 Nov; 9(22):8468-8479. PubMed ID: 32969597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study.
    Burger JA; Keating MJ; Wierda WG; Hartmann E; Hoellenriegel J; Rosin NY; de Weerdt I; Jeyakumar G; Ferrajoli A; Cardenas-Turanzas M; Lerner S; Jorgensen JL; Nogueras-González GM; Zacharian G; Huang X; Kantarjian H; Garg N; Rosenwald A; O'Brien S
    Lancet Oncol; 2014 Sep; 15(10):1090-9. PubMed ID: 25150798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia.
    Burger JA; Sivina M; Jain N; Kim E; Kadia T; Estrov Z; Nogueras-Gonzalez GM; Huang X; Jorgensen J; Li J; Cheng M; Clow F; Ohanian M; Andreeff M; Mathew T; Thompson P; Kantarjian H; O'Brien S; Wierda WG; Ferrajoli A; Keating MJ
    Blood; 2019 Mar; 133(10):1011-1019. PubMed ID: 30530801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment with idelalisib in patients with chronic lymphocytic leukemia - real world data from the registry of the German CLL Study Group.
    von Tresckow J; Heyl N; Robrecht S; Giza A; Aldaoud A; Schlag R; Klausmann M; Linde H; Stein W; Schwarzer A; Fischer K; Cramer P; Eichhorst B; Hallek M; Fink AM
    Ann Hematol; 2023 Nov; 102(11):3083-3090. PubMed ID: 37358640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.